比较巴洛沙韦和奥司他韦对门诊乙型流感患者的疗效

IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Influenza and Other Respiratory Viruses Pub Date : 2024-08-27 DOI:10.1111/irv.70002
Takahiro Takazono, Genta Ito, Naoki Hosogaya, Naoki Iwanaga, Takuji Komeda, Masayuki Kobayashi, Yoshitake Kitanishi, Eriko Ogura, Hiroshi Mukae
{"title":"比较巴洛沙韦和奥司他韦对门诊乙型流感患者的疗效","authors":"Takahiro Takazono,&nbsp;Genta Ito,&nbsp;Naoki Hosogaya,&nbsp;Naoki Iwanaga,&nbsp;Takuji Komeda,&nbsp;Masayuki Kobayashi,&nbsp;Yoshitake Kitanishi,&nbsp;Eriko Ogura,&nbsp;Hiroshi Mukae","doi":"10.1111/irv.70002","DOIUrl":null,"url":null,"abstract":"<p>This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (<i>n</i> = 4822) for preventing severe events compared with oseltamivir (<i>n</i> = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2–14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13–5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use.</p><p><b>Trial Registration:</b> UMIN Clinical Trials Registry Study ID: UMIN000051382</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70002","citationCount":"0","resultStr":"{\"title\":\"Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B\",\"authors\":\"Takahiro Takazono,&nbsp;Genta Ito,&nbsp;Naoki Hosogaya,&nbsp;Naoki Iwanaga,&nbsp;Takuji Komeda,&nbsp;Masayuki Kobayashi,&nbsp;Yoshitake Kitanishi,&nbsp;Eriko Ogura,&nbsp;Hiroshi Mukae\",\"doi\":\"10.1111/irv.70002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (<i>n</i> = 4822) for preventing severe events compared with oseltamivir (<i>n</i> = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2–14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13–5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use.</p><p><b>Trial Registration:</b> UMIN Clinical Trials Registry Study ID: UMIN000051382</p>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.70002\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

这项回顾性队列研究分析了日本医疗保险数据库中的数据,评估了与奥司他韦(n = 10523)相比,巴洛沙韦(n = 4822)对乙型流感患者预防严重事件的有效性。次要终点包括静脉注射抗菌药物、肺炎住院、心力衰竭住院、吸氧需求和使用其他抗流感药物。巴洛沙韦的住院率明显降低(0.15% 对 0.37%;风险比:2.48,95% 置信区间:1.13-5.43)。使用巴洛沙韦后,肺炎和额外抗流感治疗的发生率也降低了,因此支持使用巴洛沙韦。试验注册:UMIN 临床试验注册研究 ID:UMIN000051382.
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B

This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2–14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13–5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use.

Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
4.50%
发文量
120
审稿时长
6-12 weeks
期刊介绍: Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
期刊最新文献
Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022–August 2023 Expansion of Laboratory Capacity in the Eastern Mediterranean Region During the COVID-19 Pandemic: Lessons Learned and Future Strategies for Sustainability Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK Real-World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis Respiratory Diagnoses Year-Round: Unraveling the Multifaceted Pediatric Infection Cycles
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1